{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:52:00Z","timestamp":1769878320314,"version":"3.49.0"},"reference-count":59,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Genetic screen-and-treat strategies for the risk-reduction of breast cancer (BC) and ovarian cancer (OC) are often evaluated by cost\u2013utility analyses (CUAs). This analysis compares data on health preferences (i.e., utility values) in CUAs of targeted genetic testing for BC and OC. Based on utilities applied in fourteen CUAs, data on utility including related assumptions were extracted for the health states: (i) genetic test, (ii) risk-reducing surgeries, (iii) BC\/OC and (iv) post cancer. In addition, information about the sources of utility and the impact on the cost-effectiveness was extracted. Utility for CUAs relied on heterogeneous data and assumptions for all health states. The utility values ranged from 0.68 to 0.97 for risk-reducing surgeries, 0.6 to 0.85 for BC and 0.5 to 0.82 for OC. In two out of nine studies, considering the impact of the test result strongly affected the cost\u2013effectiveness ratio. While in general utilities seem not to affect the cost\u2013utility ratio, in future modeling studies the impact of a positive\/negative test on utility should be considered mandatory. Women\u2019s health preferences, which may have changed as a result of improved oncologic care and genetic counselling, should be re-evaluated.<\/jats:p>","DOI":"10.3390\/cancers13194879","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T08:27:44Z","timestamp":1632904064000},"page":"4879","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Data on Utility in Cost\u2013Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-7294","authenticated-orcid":false,"given":"Julia","family":"Sim\u00f5es Corr\u00eaa Galendi","sequence":"first","affiliation":[{"name":"Institute of Health Economics and Clinical Epidemiology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Gleueler Str. 174-176, 50923 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4977-750X","authenticated-orcid":false,"given":"Vera","family":"Vennedey","sequence":"additional","affiliation":[{"name":"Institute of Health Economics and Clinical Epidemiology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Gleueler Str. 174-176, 50923 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Kentenich","sequence":"additional","affiliation":[{"name":"Institute of Health Economics and Clinical Epidemiology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Gleueler Str. 174-176, 50923 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1726-9300","authenticated-orcid":false,"given":"Stephanie","family":"Stock","sequence":"additional","affiliation":[{"name":"Institute of Health Economics and Clinical Epidemiology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Gleueler Str. 174-176, 50923 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Institute of Health Economics and Clinical Epidemiology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Gleueler Str. 174-176, 50923 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1245\/s10434-015-4532-1","article-title":"Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"22","author":"Marchetti","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"Jama"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1471-0528.2011.02920.x","article-title":"Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status","volume":"118","author":"Manchanda","year":"2011","journal-title":"Bjog"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/M13-1684","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: A systematic review to update the U.S. Preventive Services Task Force recommendation","volume":"160","author":"Nelson","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0272989X03254456","article-title":"The use of gene tests to detect hereditary predisposition to chronic disease: Is cost-effectiveness analysis relevant?","volume":"23","author":"Col","year":"2003","journal-title":"Med. Decis Mak."},{"key":"ref_6","first-page":"303","article-title":"Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review","volume":"24","author":"Koldehoff","year":"2021","journal-title":"Value Health J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_7","unstructured":"Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., and Torrance, G.W. (2015). Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rai, G. (2018). Pharmacoeconomics in healthcare. Pharmaceutical Medicine and Translational Clinical Research, Academic Press. [1st ed.]. Chapter 33.","DOI":"10.1016\/B978-0-12-802103-3.00034-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhealeco.2007.07.003","article-title":"Welfarism vs. extra-welfarism","volume":"27","author":"Brouwer","year":"2008","journal-title":"J. Health Econ."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1524-4733.2009.00516.x","article-title":"QALYs: Some challenges","volume":"12","author":"Nord","year":"2009","journal-title":"Value Health: J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","article-title":"QALYs: The basics","volume":"12","author":"Weinstein","year":"2009","journal-title":"Value Health: J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"b2688","DOI":"10.1136\/bmj.b2688","article-title":"Comparison of direct and indirect methods of estimating health state utilities for resource allocation: Review and empirical analysis","volume":"339","author":"Arnold","year":"2009","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.3747\/co.21.1837","article-title":"Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer","volume":"21","author":"Ewara","year":"2014","journal-title":"Curr. Oncol."},{"key":"ref_14","first-page":"61","article-title":"Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma","volume":"13","author":"Hoyle","year":"2010","journal-title":"Value Health J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_15","first-page":"971","article-title":"Using health state utility values in models exploring the cost-effectiveness of health technologies","volume":"15","author":"Ara","year":"2012","journal-title":"Value Health J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_16","first-page":"509","article-title":"Populating an economic model with health state utility values: Moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10198-019-01038-1","article-title":"Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer","volume":"20","author":"Muller","year":"2019","journal-title":"Eur. J. Health Econ. Hepac Health Econ. Prev. Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40258-020-00599-0","article-title":"Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer","volume":"19","author":"Stock","year":"2021","journal-title":"Appl Health Econ. Health Policy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","article-title":"A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer","volume":"5","author":"Sun","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_21","first-page":"15","article-title":"The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes","volume":"2","author":"Tengs","year":"2000","journal-title":"Dis. Manag. Clin. Outcomes"},{"key":"ref_22","first-page":"2381468318821103","article-title":"The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway","volume":"4","author":"Asphaug","year":"2019","journal-title":"Mdm Policy Pr."},{"key":"ref_23","first-page":"567","article-title":"A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer","volume":"20","author":"Eccleston","year":"2017","journal-title":"Value Health J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1017\/S0266462319003519","article-title":"Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast\/ovarian cancers compared to treatment if cancer develops","volume":"36","author":"Hurry","year":"2020","journal-title":"Int J. Technol Assess. Health Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s12094-018-02026-2","article-title":"Cost-utility analysis of germline BRCA1\/2 testing in women with high-grade epithelial ovarian cancer in Spain","volume":"21","author":"Simon","year":"2019","journal-title":"Clin. Transl Oncol"},{"key":"ref_26","first-page":"547","article-title":"A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer","volume":"20","author":"Li","year":"2017","journal-title":"Value Health J. Int. Soc. Pharm. Outcomes Res."},{"key":"ref_27","unstructured":"(2021, July 13). Familial Breast Cancer: Full Cost Effectiveness Evidence Review & Reports; Update of clinical guideline 14 and 41. Last updated: 20 November 2019."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ygyno.2012.10.024","article-title":"Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: A Gynecologic Oncology Group study","volume":"128","author":"Hess","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1524-4733.2008.00418.x","article-title":"Cost-effectiveness of testing for breast cancer susceptibility genes","volume":"12","author":"Holland","year":"2009","journal-title":"Value in Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ygyno.2018.10.014","article-title":"BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer","volume":"152","author":"Kwon","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_31","first-page":"985","article-title":"Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers","volume":"20","author":"Tuffaha","year":"2018","journal-title":"Genet. Med. Off. J. Am. Coll. Med Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1023\/A:1013123915272","article-title":"Measuring women\u2019s preferences for breast cancer treatments and BRCA1\/BRCA2 testing","volume":"10","author":"Cappelli","year":"2001","journal-title":"Qual Life Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1705032","article-title":"A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation","volume":"36","author":"Cumming","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.2910490411","article-title":"The impact of a breast cancer screening programme on quality-adjusted life-years","volume":"49","year":"1991","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1245\/s10434-006-9206-6","article-title":"Quality of life after bilateral prophylactic mastectomy","volume":"14","author":"Geiger","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0895-4356(93)90011-O","article-title":"Framing and labelling effects in health descriptions: Quality adjusted life years for treatment of breast cancer","volume":"46","author":"Gerard","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"ref_37","first-page":"283","article-title":"The quality of life associated with prophylactic treatments for women with BRCA1\/2 mutations","volume":"5","author":"Grann","year":"1999","journal-title":"Cancer J. Sci Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-009-0373-6","article-title":"Breast cancer-related preferences among women with and without BRCA mutations","volume":"119","author":"Grann","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/sj.bjc.6601792","article-title":"Cancer genetics services: A systematic review of the economic evidence and issues","volume":"90","author":"Griffith","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/sj.bjc.6601903","article-title":"The impact of the perception of treatment choice on satisfaction with treatment, experienced chemotherapy burden and current quality of life","volume":"91","author":"Jansen","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s11136-007-9202-8","article-title":"Health related quality of life in different states of breast cancer","volume":"16","author":"Lidgren","year":"2007","journal-title":"Qual Life Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_44","first-page":"553","article-title":"Health-state utility values in breast cancer","volume":"10","author":"Peasgood","year":"2010","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/00005650-200211000-00008","article-title":"Patient choice of breast cancer treatment: Impact on health state preferences","volume":"40","author":"Polsky","year":"2002","journal-title":"Med. Care"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2006.09.007","article-title":"Putting the \u2018Q\u2019 in quality adjusted life years (QALYs) for advanced ovarian cancer\u2014An approach using data clustering methods and the internet","volume":"43","author":"Stein","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med. Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/0272989X9801800303","article-title":"Assessment of the time-tradeoff values for prophylactic mastectomy of women with a suspected genetic predisposition to breast cancer","volume":"18","author":"Unic","year":"1998","journal-title":"Med. Decis Mak."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1001\/jama.1996.03530480027036","article-title":"BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes","volume":"275","author":"Lerman","year":"1996","journal-title":"JAMA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2003.10.100","article-title":"Long-term psychological impact of carrying a BRCA1\/2 mutation and prophylactic surgery: A 5-year follow-up study","volume":"21","author":"Lodder","year":"2003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.1998.16.3.979","article-title":"Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients","volume":"16","author":"Grann","year":"1998","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12160-008-9060-9","article-title":"The trajectory of psychological impact in BRCA1\/2 genetic testing: Does time heal?","volume":"36","author":"Beran","year":"2008","journal-title":"Ann. Behav Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2010.33.1561","article-title":"Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: Does time heal women\u2019s concerns?","volume":"29","author":"Halbert","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s10897-015-9899-4","article-title":"High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling","volume":"25","author":"Sie","year":"2016","journal-title":"J. Genet. Couns"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"PEBC\u2019s Ovarian Oncology Guidelines Group (2017). A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer. Gynecol. Oncol., 146, 392\u2013398.","DOI":"10.1016\/j.ygyno.2017.05.039"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","article-title":"Discounting in Economic Evaluations","volume":"36","author":"Attema","year":"2018","journal-title":"PharmacoEconomics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0272989X13505910","article-title":"Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: A nonparametric regression approach","volume":"34","author":"Strong","year":"2014","journal-title":"Med. Decis Mak."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00198-006-0257-0","article-title":"Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model","volume":"18","author":"Zethraeus","year":"2007","journal-title":"Osteoporos Int"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40273-015-0274-y","article-title":"Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions","volume":"33","author":"Frederix","year":"2015","journal-title":"Pharmacoeconomics"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4879\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:07:10Z","timestamp":1760166430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":59,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13194879"],"URL":"https:\/\/doi.org\/10.3390\/cancers13194879","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]}}}